Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Therapeutic Efficiency and Response to 177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05013086
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:26.729566+00:00
Published At
2024-06-13T00:00:00+00:00
Record Updated At
2024-06-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Integrin \u03b1V\u03b23 Positive Tumors"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-06-13"
protocolSection.identificationModule.nctId
"NCT05013086"
protocolSection.identificationModule.officialTitle
"Therapeutic Efficiency and Response to 177Lu-AB-3PRGD2 in Patients With Integrin \u03b1V\u03b23 Positive Tumors"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["EARLY_PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Integrin αVβ3 Positive Tumors (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.